Seattle Genetics (SGEN) Reports Q2 EPS of $0.47, Revenues Beat; Offers FY18 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seattle Genetics (SGEN) PT Raised to $79 at Needham & Company
July 27, 2018 12:22 PM EDTNeedham & Company raised its price target on Seattle Genetics (NASDAQ: SGEN) to $79.00 (from $74.00) while maintaining a Buy rating.
Analyst Chad Messer commented, "Seattle handily beat Street consensus with 2Q:18 ADCETRIS sales of $122M, higher than our $109M and similar Street... More
Seattle Genetics (SGEN) PT Raised to $64 at Cowen
July 27, 2018 11:29 AM EDTCowen raised its price target on Seattle Genetics (NASDAQ: SGEN) to $64.00 (from $54.00) while maintaining a Outperform rating
Analyst Boris Peaker noted strength was driven by strong adoption in the frontline HL by community docs, although he said the recent stock run-up factors in this stronger uptake.
... MoreSeattle Genetics (SGEN) PT Raised to $81 at SunTrust Robinson Humphrey
July 27, 2018 8:05 AM EDTSunTrust Robinson Humphrey raised its price target on Seattle Genetics (NASDAQ: SGEN) to $81.00 (from $80.00) while maintaining a Buy rating.
Analyst Yatin Suneja commented, "Adcetris surprised with another stronger than expected 2Q18 sales (+14%/$14.8MM vs. consensus), on robust uptake in frontline (1L) cHL.... More
Seattle Genetics (SGEN) PT Raised to $80 at Barclays
July 27, 2018 4:45 AM EDTBarclays raised its price target on Seattle Genetics (NASDAQ: SGEN) to $80.00 (from $74.00) while maintaining a Overweight rating.
... More